 |
| VTEQ License Several Patents from NC State PSID Still Green |
|
 Hot Stock to Watch
|
Company: VeriTeQ Corp. (OTCQB: VTEQ)
|
End of Day:
Price: 0.0033
Change (%): - 0.0004 (10.81)
Volume: 9,932,984 |
 |
VeriTeQ Corporation Enters Agreement Providing Exclusive License of Multiple Patents From NC State University
DELRAY BEACH, Fla., Oct. 9, 2014 (GLOBE NEWSWIRE) - VeriTeQ Corporation (“VeriTeQ” or “Company”) (OTC Markets:VTEQ), a provider of implantable medical device identification and radiation dose measurement technologies, announced today that it has entered an agreement providing an exclusive license of multiple patents from North Carolina State University (“NCSU”). VeriTeQ will license 24 patents, which are the foundation for its FDA cleared Q Inside SmartMarker and OneDose products for radiation dosimetry.
Q Inside SmartMarker (formerly known as DVS SmartMarker) is an implantable radiation sensor for use in breast and prostate cancer patients undergoing photon external beam treatments. It is implanted in, or adjacent to, solid-mass tumors and gathers data on the actual dose of radiation being delivered to the tumor and surrounding normal tissue. Q Inside SmartMarker is intended to be used in the balancing between delivering maximum dose to the tumor while minimizing the impact to healthy tissue. The sensor can confirm the treatment is conforming to the physician’s plan, as even a small deviation from the planned dose can have a significant impact on patient survival rates.
Continue Reading
|
 Yesterday's Top Performer
|
Company: PositiveID Corporation (OTCQB: PSID)
|
End of Day:
Price: 0.0392
Change (%): + 0.0082 (26.45)
Volume: 5,004,821 |
 |
About PositiveID Corporation
PositiveID Corporation is an emerging growth company and developer of biological detection systems for America's homeland defense industry as well as rapid biological testing. PositiveID is focused on the development of microfluidic systems for the automated preparation of and performance of biological assays in order to detect biological threats at high-value locations, as well as analyze samples in a medical environment.
Company Information Sheet |
Other Small Cap News
|
Company: Boston Therapeutics, Inc. (OTCQB: BTHE)
|
Boston Therapeutics Reports Topline U.S.-Based Phase IIb Study Results of BTI-320 in Patients With Type 2 Diabetes
Results From Four Trials to Support Tests Methods and Dose Configuration for the Phase III Study Slated for 2015
MANCHESTER, NH--(Marketwired - Oct 9, 2014) - Boston Therapeutics, Inc. (OTCQB: BTHE) ("Boston Therapeutics" or "the Company"), a developer of complex carbohydrate therapeutics to manage post meal blood glucose levels and inflammatory diseases, reports results from its Phase IIb clinical study of BTI-320 in patients with type 2 diabetes (SD-002) conducted in the U.S. by Accumed Research Associates in Garden City, NY.
SD-002 is one of three completed studies evaluating one group of overweight healthy subjects and two groups of type 2 diabetes patients' glycemic response to different doses of our drug BTI-320. The SD-002 trial enrolled patients with type 2 diabetes diagnosed for at least one year and who are on stable dose of daily metformin for at least three months. The SD-002 patients were administered BTI-320 and metformin using a randomized, double-blind, placebo-controlled, dose-ranging, three-way cross-over study design.
Continue Reading
|
Company: COPsync, Inc. (OTCQB: COYN)
|
COPsync Retains Investment Banking Firm Maxim Group
Firm to Serve as Exclusive Investment Banker and Corporate Financial Advisor
DALLAS, Oct. 9, 2014 (GLOBE NEWSWIRE) -- COPsync, Inc. (OTCQB: COYN), which operates the nation's largest law enforcement real-time, in-car information sharing, communication and data interoperability network and the COPsync 911 threat alert service for schools, government buildings, hospitals and other potentially at-risk targets, today announced the engagement of New York City-based Maxim Group LLC to serve as the Company's exclusive investment banker and corporate financial advisor.
"We are very pleased to be working with the Maxim Group, who will be providing us assistance with respect to capital formation strategies and potential accretive acquisition opportunities," said Ronald A. Woessner, chief executive officer for COPsync, Inc.
Continue Reading |
Market News
|
By Peter Schacknow: CNBC
|
Early Movers: PEP, AUXL, ENDP, HLT, MW, AA, RT & more
Check out which companies are making headlines before the bell on Thursday:
PepsiCo (PEP) - The beverage and snacks maker reported quarterly profit of $1.36 per share, beating estimates by seven cents. Revenue beat consensus as well, and Pepsi also raised its full-year forecast in the face of what CEO Indra Nooyi calls a "challenged macroeconomic environment".
Auxilium Pharmaceuticals (AUXL) - Endo International (ENDP) is buying Auxilium in a deal worth $2.6 billion, including the assumption of debt. Auxilium terminated its prior merger agreement with Canada's QLT (QLTI) as a result of the Endo deal.
Impax Laboratories (IPXL) - Impax bought privately held drug makers Tower Holdings and Lineage Therapeutics for a total of 700 million dollars in cash.
Continue Reading
|
By Jason Lange: Reuters
|
U.S. jobless claims fall, point to labor market strength
WASHINGTON (Reuters) - The number of Americans filing new claims for unemployment benefits fell last week to nearly its lowest level since before the 2007-09 recession, a sign of growing steam in the U.S. labor market.
Initial claims for state unemployment benefits dropped 1,000 to a seasonally adjusted 287,000 in the week ended Oct. 4, the Labor Department said on Thursday.
The data adds to the view that some strength is building in the U.S. economy.
Continue Reading
|
  |
IMPORTANT DISCLAIMER - PLEASE READ THOROUGHLY
SmallCapVoice (SCV) is an electronic publication. Information sources for our profiles include, but are not limited to, online research, member suggestions, magazines, newspapers, analyst suggestions, information provided by the profiled company, press releases and similar sources. This communication is not an offer to sell or a recommendation that you buy or sell any security. SCV holds no securities licenses and is not qualified to provide investment advice. We are compensated for these advertisements by the profiled companies. You should not use this newsletter as the sole basis for any investment decision. While all investments involve risk, microcap stocks are among the most risky. Many microcap companies have no proven track record. You should only invest in microcap companies if you can afford to lose your entire investment. You should consult a qualified, licensed financial advisor or stock broker before making any decisions to invest in the securities of any company that is described in these profiles. These profiles are paid advertisements. Although we have a reasonable belief that the information in each profile is accurate, we cannot guarantee that the information is accurate. It is important for you to verify all information by your own independent research. You are receiving this message because you have agreed to receive emails from SmallCapVoice.com. You may opt out of our distribution list at any time by clicking on the "unsubscribe" link below. Link to full disclosure about compensation paid to SmallCapVoice.com, Inc. by companies featured on our website or in our e-mail communications. |
About Penny Stocks |
|
|
